[Study progress of tyrosine kinase inhibitor discontinuation in children with chronic myeloid leukemia].
作者信息
Zheng F Y, Wang M, Zhang L P, Jiang Q
机构信息
Department of Pediatrics, Peking University People's Hospital, Beijing 100044, China.
Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, Beijing 100044, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2023 Feb 14;44(2):174-176. doi: 10.3760/cma.j.issn.0253-2727.2023.02.019.
Abstract
摘要
相似文献
1
[Study progress of tyrosine kinase inhibitor discontinuation in children with chronic myeloid leukemia].[慢性髓性白血病患儿酪氨酸激酶抑制剂停药的研究进展]
Zhonghua Xue Ye Xue Za Zhi. 2023 Feb 14;44(2):174-176. doi: 10.3760/cma.j.issn.0253-2727.2023.02.019.
2
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF.为什么并非所有符合条件的慢性髓性白血病患者都愿意尝试停用酪氨酸激酶抑制剂？一项与TKI停药试验HALF相关的捷克全国性分析。
Leukemia. 2024 Apr;38(4):893-897. doi: 10.1038/s41375-024-02215-9. Epub 2024 Mar 12.
3
Predictive value of early molecular response to tyrosine kinase inhibitors in pediatric patients with chronic myeloid leukemia.
Leuk Lymphoma. 2024 Jul;65(7):1024-1027. doi: 10.1080/10428194.2024.2331625. Epub 2024 Mar 21.
4
Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR::ABL1 digital PCR in chronic myeloid leukemia patients.酪氨酸激酶抑制剂停药后 BCR::ABL1 数字 PCR 预测慢性髓性白血病患者的持续缓解。
Eur J Haematol. 2024 Nov;113(5):606-613. doi: 10.1111/ejh.14271. Epub 2024 Jul 12.
5
Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation.慢性髓性白血病中继发性融合作为酪氨酸激酶抑制剂耐药和急变期转化驱动因素的出现。
Leuk Res. 2024 Feb;137:107439. doi: 10.1016/j.leukres.2024.107439. Epub 2024 Jan 23.
6
Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.慢性粒细胞白血病中的新型酪氨酸激酶抑制剂
Curr Opin Oncol. 2006 Nov;18(6):578-83. doi: 10.1097/01.cco.0000245314.97638.d3.
7
Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients.
Br J Haematol. 2024 Apr;204(4):1536-1539. doi: 10.1111/bjh.19330. Epub 2024 Feb 7.
8
[Discontinuation of tyrosine kinase inhibitors before epiphyseal closure leading to improved short stature in pediatric chronic myelogenous leukemia].
Rinsho Ketsueki. 2024;65(3):175-179. doi: 10.11406/rinketsu.65.175.
9
BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.用于治疗慢性粒细胞白血病的BCR-ABL1酪氨酸激酶抑制剂
J Oncol Pharm Pract. 2018 Sep;24(6):433-452. doi: 10.1177/1078155217710553. Epub 2017 Jun 4.
10
De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors.即使在酪氨酸激酶抑制剂时代，也应识别慢性髓性白血病的新生加速期。
Am J Hematol. 2024 Apr;99(4):763-766. doi: 10.1002/ajh.27229. Epub 2024 Feb 5.
本文引用的文献
1
Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.慢性髓细胞白血病：诊断、治疗和监测的 2022 年更新。
Am J Hematol. 2022 Sep;97(9):1236-1256. doi: 10.1002/ajh.26642. Epub 2022 Jul 6.
2
Health-related quality of life in children with chronic myeloid leukemia in the chronic phase.慢性期慢性髓性白血病患儿的健康相关生活质量
J Cancer Res Clin Oncol. 2022 Feb;148(2):341-350. doi: 10.1007/s00432-021-03832-y. Epub 2021 Oct 29.
3
Treatment-Free Remission in Chronic Myeloid Leukemia: Can We Identify Prognostic Factors?慢性髓性白血病的无治疗缓解：我们能否识别预后因素？
Cancers (Basel). 2021 Aug 19;13(16):4175. doi: 10.3390/cancers13164175.
4
Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML.慢性粒细胞白血病患儿停用伊马替尼：一项来自儿童慢性粒细胞白血病国际登记处的研究
Cancers (Basel). 2021 Aug 15;13(16):4102. doi: 10.3390/cancers13164102.
5
Chronic Myelogenous Leukemia in Childhood.儿童慢性髓性白血病。
Curr Oncol Rep. 2021 Mar 14;23(4):40. doi: 10.1007/s11912-021-01025-x.
6
Definition, Epidemiology, Pathophysiology, and Essential Criteria for Diagnosis of Pediatric Chronic Myeloid Leukemia.儿童慢性髓系白血病的定义、流行病学、病理生理学及诊断基本标准
Cancers (Basel). 2021 Feb 14;13(4):798. doi: 10.3390/cancers13040798.
7
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.慢性髓性白血病临床实践指南（2021 年版），NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2020 Oct 1;18(10):1385-1415. doi: 10.6004/jnccn.2020.0047.
8
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.欧洲白血病网络 2020 年治疗慢性髓性白血病的建议。
Leukemia. 2020 Apr;34(4):966-984. doi: 10.1038/s41375-020-0776-2. Epub 2020 Mar 3.
9
Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukaemia.慢性髓性白血病儿童和青少年间歇性伊马替尼（ON/OFF方案）的结果与转归
Br J Haematol. 2020 Mar;188(6):e101-e105. doi: 10.1111/bjh.16388. Epub 2020 Feb 22.
10
Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta-analysis of studies over the last ten years.酪氨酸激酶抑制剂停药后慢性髓性白血病患者发生分子复发的风险：对过去十年研究文献的系统评价和荟萃分析。
Br J Haematol. 2020 May;189(3):452-468. doi: 10.1111/bjh.16408. Epub 2020 Feb 19.
Zotero 插件